Entries by Michael Kuhrt

Confo Therapeutics: High calibre chair

Drug discovery company Confo Therapeutics has appointed John Edward Berriman as non-executive director and chairman of the board of directors. Berriman is set to take his seat on the board December 21.

F2G: Medical reference

Antifungal drug developer F2G Ltd has appointed distinguished research scientist John Rex to the position of Chief Medical Officer.

Merck: Strategic hike

At the beginning of October, Isabel De Paoli assumed the position of Chief Strategy Officer at German healthcare company Merck GmbH. She will head the Group Strategy and Transformation Function, which has just been created.

Curetis bags EIB debt financing and expands

Dutch-German molecular diagostics specialist Curetis has bagged debt finanancing from the European Investment Bank (EIB) to expand its automated multiplex PCR platform Univero. The company will receive €10m immediately. Further €15m are milestone-dependent.

Pharmalink: Gaining momentum

In order to prepare for the start of Phase III trials with its lead drug candidate Nefecon, Pharmalink AB has made several new appointments. Among them Kari Sandvold, who will take over as Vice President Pharmaceutical Development and Manufacturing.

Crenezumab data support Amyloid-beta targeting

While competitor Eli Lilly has abandoned commercialisation of its Alzheimer’s therapy solanezumab due to lack of efficacy in a pivotal Phase III study, Genentech has tabled data supporting further development of its Phase III drug crenezumab. The anti-Abeta antibody is highly homologous to solanezumab.

Symphogen: Big shoes to fill

Copenhagen-based Symphogen is losing its long-time CEO Kirsten Drejer, who co-founded the Danish antibody specialist in 2000. In her place, erstwhile CFO Martin Olin is taking over the helm.

Merck expands portfolio of liquid biopsy tests

Merck KGaA has expanded its portfolio of blood-based RAS diagnostics for use in patient stratification. After kicking off testing with Sysmex Inostics’ CE-marked OncoBEAM RAS CRC liquid biopsy assay last year, the German drug maker welcomed the launch of a second blood-based test to detect KRAS mutations in patients with colorectal cancer (CRC): Biocartis’  Idylla ctKRAS Mutation Assay.

TiGenix launches IPO in the US

Euronext Brussels-noted adipose stem cell player TiGenix NV wants to offer 2.75 million American Depositary Shares (ADS) in an IPO at Nasdaq Global Market representing 55 million of its ordinary shares which had went up from  €0.91 yesterday to €0.96 (10.a.m.).